Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia: A 12- and 24-Month Follow-Up from the e-STAR Database in Spain

Author： Olivares José M.  

Publisher： Adis International

ISSN： 1175-5652

Source： Applied Health Economics and Health Policy, Vol.6, Iss.1, 2008-01, pp. : 41-53

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Long-Acting Risperidone in Sweden

By Hensen Marja  

Applied Health Economics and Health Policy, Vol. 8, Iss. 5, 2010-09 ,pp. : 327-341

Adis International

Access to resources Recommend Favorite

Management of Schizophrenia: Defining the Role of Long-Acting Injectable Risperidone

By Curran Monique P.   Keating Gillian M.  

Disease Management & Health Outcomes, Vol. 14, Iss. 2, 2006-01 ,pp. : 107-125

Adis International

Access to resources Recommend Favorite

Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis

By Garuz R.   Torrea J.L.   Arnal J.M.   Forcen T.   Trinxet C.   Anton F.   Antonanzas F.  

Vaccine, Vol. 15, Iss. 15, 1997-10 ,pp. : 1652-1660

Elsevier

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Entecavir versus Lamivudine in the First-Line Treatment of Australian Patients with Chronic Hepatitis B

By Arnold Elizabeth  

Applied Health Economics and Health Policy, Vol. 6, Iss. 4, 2008-01 ,pp. : 231-246

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Treatments for Vertebral Compression Fractures

By Edidin Avram A.  

Applied Health Economics and Health Policy, Vol. 10, Iss. 4, 2012-07 ,pp. : 273-284

Adis International

Access to resources Recommend Favorite